An African health tech innovator identified as Sproxil, has announced a partnership with Nigeria’s National Malaria Elimination Programme (NMEP) and the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) to strengthen the fight against malaria across the country.
The collaboration is formalized through some Memorandum of Understanding at the Access to Markets event hosted by Investing in Innovation Africa (i3), aims to improve access to malaria diagnostics and treatments while providing critical real-time surveillance data to health authorities.
Sproxil’s groundbreaking test, treat, and track model, driven by artificial intelligence, provides unparalleled insight into the distribution and treatment trends of malaria throughout Nigeria.
The AI system analyzes rapid diagnostic tests conducted by healthcare professionals, pharmacies, and patent medicine vendors, assessing whether the results are positive, negative, or invalid. This creates Nigeria’s inaugural real-time Test Positivity Rate map, offering the NMEP valuable insights to monitor disease trends, oversee medication distribution, and ensure accountability within the healthcare supply chain.
News: Peller Crashes Car During Emotional Livestream
This initiative bolsters Nigeria’s Affordable Diagnostics and Medicine for Malaria Funding Model (ADMFm), a co-payment system where the government and pharmaceutical manufacturers collaborate to lower the costs of ACTs and rapid diagnostic tests. This guarantees affordability and broad availability, especially in rural regions where the malaria burden is most severe.
Sproxil will implement NAFDAC-required traceability and mobile authentication services on ACTs distributed through the program, safeguarding patients from counterfeit medications while providing the surveillance data that NMEP requires to achieve its goals of reducing malaria prevalence to below 10% and lowering deaths to under 50 per 1,000 live births.
“We are privileged to collaborate with NMEP and PVAC in establishing AI-enhanced surveillance infrastructure that converts every consumer product verification into timely epidemiological intelligence,” stated Dr. Ashifi Gogo, CEO and Founder of Sproxil.
“This partnership illustrates that African-led initiatives, when adequately supported, can facilitate health transformation across the continent while ensuring that affordable antimalarials reach the children and families who need them the most.”
Sproxil is an African health technology company that utilizes AI and mobile technology to enhance access to quality healthcare and fight against counterfeit medications.
